CliniSys, one of the UKÆs leading providers of pathology software solutions, has announced its acquisition of MIPS, one of the largest and most successful suppliers of laboratory information systems in Europe. Head-quartered in Belgium, MIPS has a strong track record of sales success throughout Europe and a long history of product and service innovation.
CliniSys acquires MIPS, a leading European pathology software supplier
"This acquisition brings together two highly successful pathology software suppliers; CliniSys has won the majority of competitive procurements in the UK over the past few years and MIPS dominates the Benelux market and is now making fast inroads into the French, German and Spanish market", said Donald Saum, Business Development Driector at Clinisys Pathology.
The combined customer base covering over 400 sites across Europe will now benefit from the dedicated expertise of 200 pathology specialists focusing on the development, delivery and support of solutions to improve the efficiency and effectiveness of the clinical laboratory and medical practice.
CliniSys is a leading UK player in chronic disease management applications, an area in which MIPS also brings a complimentary skill set supporting oncology, sexual health and diabetes.
Healthcare IT across Europe is benefiting from a significant increase in investment and higher prioritisation. Best practice from many nations will inform the GroupÆs new product development strategy to serve the wider customer base. In particular, the enlarged customer base will benefit from CliniSysÆ direct experience of participating in the UKÆs ú6.2bn Connecting for Health IT programme.
The fast and accurate delivery of pathology results is at the heart of many healthcare improvement programmes which demand solutions that meet both the evolving needs of the laboratory scientist and the diagnosing clinicianÆs need for integrated information at the point of care. These requirements combined with the development of an integrated chronic disease management offering will continue to drive CliniSysÆ organic and acquisitive growth strategy.